checkAd

     384  0 Kommentare DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 - Seite 2

    "Skin Dendritic Cells Progressively Subvert The Activation Of Pathogenic Type-2 Immunity Upon Epicutaneous Allergen Immunotherapy" will be presented by Dr. Leo Laoubi, DBV Technologies.

    • Poster Number: 734
    • Session Number: 4208
    • Session Title: Food Immunotherapy
    • Poster Hall Location: Moscone Center South, Exhibition Level, Hall B
    • Presentation Date: Monday, February 25, 2019
    • Presentation Time: 9:45am-10:45am

    "Langerhans Cells Increase Their Expression of Integrin avb8 Through Migration and are Needed for Tregs Induction by Epicutaneous Immunotherapy (EPIT)" will be presented by Dr. Vincent Dioszeghy, DBV Technologies.

    • Poster Number: 622
    • Session Number: 3802
    • Session Title: BCI Featured Poster Session
    • Poster Hall Location: Moscone Center South, Exhibition Level, Hall B
    • Presentation Date: Sunday February 24, 2019
    • Presentation Time: 4:30 - 6:00pm

    Cashew Nut Allergy Data

    "Development of a Cashew Nut Allergy Mouse Model to Evaluate the Efficacy of Epicutaneous Desensitization Treatment" will be presented by Dr. Pierre-Louis Hervé, DBV Technologies.

    • Poster Number: 787
    • Session Number: 4209
    • Session Title: Food Allergy and Treatment
    • Poster Hall Location: Moscone Center South, Exhibition Level, Hall B
    • Presentation Date: Monday, February 25, 2019
    • Presentation Time: 9:45am-10:45am

    DBV-Sponsored Research

    "Shared Cooking Equipment in Restaurants: A Quantitative Risk Assessment for Peanut-Allergic Consumers" will be presented by Dr. Benjamin C. Remington, TNO Ziest, The Netherlands.

    • Poster Number: 724
    • Session Number: 4207
    • Session Title: Food Allergen Structures
    • Poster Hall Location: Moscone Center South, Exhibition Level, Hall B
    • Presentation Date: Monday, February 25, 2019
    • Presentation Time: 9:45am-10:45am

    "Double-Blind, Placebo-Controlled Randomized Trial of Epicutaneous Immunotherapy in Children with Milk-Induced Eosinophilic Esophagitis" will be presented by Dr. Jonathan Spergel, Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.

    Seite 2 von 4



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 - Seite 2 Montrouge, France, February 4, 2019 DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 Novel immunotherapy based on Viaskin technology highlighted as a potential treatment for food-allergic patients DBV Technologies …